Cabozantinib (XL184) for the treatment of locally advanced or metastatic progressive medullary thyroid cancer

2013 ◽  
Vol 9 (8) ◽  
pp. 1083-1092 ◽  
Author(s):  
David Viola ◽  
Virginia Cappagli ◽  
Rossella Elisei
Keyword(s):  
Thyroid Cancer ◽  
Medullary Thyroid Cancer ◽  
Locally Advanced ◽  
Medullary Thyroid

scholarly journals Vandetanib (ZD6474) in the Treatment of Medullary Thyroid Cancer

2011 ◽  
Vol 5 ◽  
pp. CMO.S6197 ◽  
Author(s):  
Hari Deshpande ◽  
Sanziana Roman ◽  
Jaykumar Thumar ◽  
Julie Ann Sosa
Keyword(s):  
Thyroid Cancer ◽  
Growth Factor ◽  
Phase Ii ◽  
Medullary Thyroid Cancer ◽  
Kinase Inhibitor ◽  
Locally Advanced ◽  
Growth Factor Receptor ◽  
Good Choice ◽  
Phase Ii Trials ◽  
Medullary Thyroid

Vandetanib (ZD6474) is an orally bioavailable small molecule tyrosine kinase inhibitor of multiple growth factor receptors, including RET (Rearrange during transfection), vascular endothelial growth factor receptor-2 (VEGFR-2) and epidermal growth factor receptor (EGFR). The activity against RET and VEGF made it a good choice in the treatment of medullary thyroid cancer (MTC). As there is considerable cross talk between growth factor pathways, dual inhibition with such agents has become an attractive strategy, in the treatment of many malignancies with encouraging Phase II clinical trial data to date. Vandetanib was tested in two Phase II trials in the treatment of patients with medullary thyroid cancer at doses of 100 mg and 300 mg daily respectively. The encouraging results of these 2 trials led to a randomized phase II trial comparing this medication to placebo using a crossover design. More than 300 patients were included in this study, which ultimately showed a significant improvement in progression-free survival in patients taking vandetanib. Based on these results, the Oncology Drug Advisory Committee (ODAC) of the Food and Drug Administration (FDA) recommended that vandetanib be approved for the treatment of patients with unresectable locally advanced or metastatic medullary thyroid cancer.

Anlotinib for the Treatment of Patients with Locally Advanced or Metastatic Medullary Thyroid Cancer

Thyroid ◽  
2018 ◽  
Vol 28 (11) ◽  
pp. 1455-1461 ◽  
Author(s):  
Yongkun Sun ◽  
Feng Du ◽  
Ming Gao ◽  
Qinghai Ji ◽  
Zhendong Li ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Medullary Thyroid Cancer ◽  
Locally Advanced ◽  
Medullary Thyroid

scholarly journals Vandetanib (100 mg) in Patients with Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer

2010 ◽  
Vol 95 (6) ◽  
pp. 2664-2671 ◽  
Author(s):  
Bruce G. Robinson ◽  
Luis Paz-Ares ◽  
Annetta Krebs ◽  
James Vasselli ◽  
Robert Haddad
Keyword(s):  
Thyroid Cancer ◽  
Growth Factor ◽  
Medullary Thyroid Cancer ◽  
Response Rate ◽  
Objective Response ◽  
Locally Advanced ◽  
Growth Factor Receptor ◽  
Once Daily ◽  
Medullary Thyroid ◽  
Hereditary Medullary Thyroid Cancer

Abstract Purpose: Vandetanib is a once-daily oral inhibitor of vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinases that also inhibits rearranged during transfection kinase activity. Vandetanib (300 mg/d) has previously demonstrated antitumor activity in patients with advanced hereditary medullary thyroid cancer (MTC). This study investigated the efficacy and safety of 100 mg/d vandetanib in patients with advanced hereditary MTC. Patients and Methods: Eligible patients with unresectable, measurable, locally advanced, or metastatic hereditary MTC received 100 mg/d vandetanib. Upon disease progression, eligible patients could enter postprogression treatment with 300 mg/d vandetanib until a withdrawal criterion was met. The primary objective was to assess the objective response rate by response evaluation criteria in solid tumors. Results: The study comprised 19 patients (13 males, six females; mean age 45 yr). Confirmed objective partial responses were observed in three patients, yielding an objective response rate of 16% (95% confidence interval 3.4–39.6). Stable disease lasting 24 wk or longer was reported in a further 10 patients (53%); the disease control rate was therefore 68% (95% confidence interval 43.4–87.4). Serum levels of calcitonin and carcinoembryonic antigen showed a sustained 50% or greater decrease from baseline in 16% (three of 19) and 5% (one of 19) of patients, respectively. Adverse events were predominantly grade 1 or 2 and consistent with previous vandetanib monotherapy studies. Conclusions: Vandetanib at a once-daily dose of 100 mg has clinically relevant antitumor activity in patients with locally advanced or metastatic hereditary MTC and an overall acceptable safety profile.

scholarly journals Efficacy of vandetanib in the treatment of medullary thyroid cancer: literature review and case report

2019 ◽  
Vol 9 (3) ◽  
pp. 38-48
Author(s):  
А. М. Mudunov ◽  
Yu. V. Alymov ◽  
I. S. Romanov ◽  
S. О. Podvyaznikov ◽  
А. V. Ignatova
Keyword(s):  
Clinical Trials ◽  
Thyroid Cancer ◽  
Tyrosine Kinases ◽  
Medullary Thyroid Cancer ◽  
Locally Advanced ◽  
Distant Metastases ◽  
Individual Characteristics ◽  
Medullary Thyroid ◽  
Mechanisms Of Carcinogenesis ◽  
Thyroid Malignancies

Medullary thyroid cancer (MTC) is a rare disorder that accounts for approximately 1.7 % of all thyroid malignancies. MTC is usually detected at early stages; however, approximately 10–15 % of patients are diagnosed with locally advanced MTC and distant metastases. Treatment of such patients is challenging due to biological characteristics of the disease and very few effective treatment approaches available. The investigation of mechanisms of carcinogenesis, as well as advances in pharmacology, allowed the development of a new group of targeted drugs, namely tyrosine kinases, which efficacy against progressive unresectable locally advanced or metastatic MTC has been demonstrated in multiple clinical trials. Vandetanib has been registered for MTC treatment in the Russian Federation. MTC is very rare, thus, each case of vandetanib use for its treatment is particularly interesting. Moreover, since the approval of this drug in 2011 by the U. S. Food and Drug Administration (FDA), new data on the clinical use of vandetanib have been accumulated. Importantly, clinical trials are usually well designed and conducted in near-ideal conditions, whereas the real conditions can be different and patients may have individual characteristics. Therefore, the aim of this study was to update the information on the efficacy and safety of vandetanib by retrospective analysis of available publications and to report a case of MTC treated with vandetanib.

Vandetanib (VAN) in locally advanced or metastatic medullary thyroid cancer (MTC): A randomized, double-blind phase III trial (ZETA).

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. 5503-5503 ◽  
Author(s):  
S. A. Wells ◽  
B. G. Robinson ◽  
R. F. Gagel ◽  
H. Dralle ◽  
J. A. Fagin ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Medullary Thyroid Cancer ◽  
Locally Advanced ◽  
Phase Iii ◽  
Double Blind ◽  
Phase Iii Trial ◽  
Medullary Thyroid
Sign in / Sign up

Export Citation Format

Share Document